Literature DB >> 14647429

Gadd45a regulates matrix metalloproteinases by suppressing DeltaNp63alpha and beta-catenin via p38 MAP kinase and APC complex activation.

Jeffrey Hildesheim1, Galina I Belova, Stuart D Tyner, Xiwu Zhou, Lilit Vardanian, Albert J Fornace.   

Abstract

The p53-regulated growth arrest and DNA damage-inducible gene product Gadd45a has been recently identified as a key factor protecting the epidermis against ultraviolet radiation (UVR)-induced skin tumors by activating p53 via the stress mitogen-activated protein kinase (MAPK) signaling pathway. Herein we identify Gadd45a as an important negative regulator of two oncogenes commonly over-expressed in epithelial tumors: the p53 homologue DeltaNp63alpha and beta-catenin. DeltaNp63alpha is one of the several p63 isoforms and is the predominant species expressed in basal epidermal keratinocytes. DeltaNp63alpha lacks the N-terminal transactivation domain and behaves as a dominant-negative factor blocking expression of several p53-effector genes. DeltaNp63alpha also associates with and blocks activation of the adenomatous polyposis coli (APC) destruction complex that targets free cytoplasmic beta-catenin for degradation. While most beta-catenin protein is localized to the cell membrane and is involved in cell-cell adhesion, accumulation of free cytoplasmic beta-catenin will translocate into the nucleus where it functions in a bipartite transcription factor complex, whose targets include invasion and metastasis promoting endopeptidases, matrix metalloproteinases (MMP). We show that Gadd45a not only directly associates with two components of the APC complex, namely protein phosphatase 2A (PP2A) and glycogen synthase kinase 3beta (GSK3beta) but also promotes GSK3beta dephosphorylation at Ser9, which is essential for GSK3beta activation, and resultant activation of the APC destruction complex. We demonstrate that lack of Gadd45a not only prevents DeltaNp63alpha suppression and GSK3beta dephosphorylation but also prevents free cytoplasmic beta-catenin degradation after UV irradiation. The inability of Gadd45a-null keratinocytes to suppress beta-catenin may contribute to the resulting observation of increased MMP expression and activity along with significantly faster keratinocyte migration in Matrigel in vitro and accelerated wound closure in vivo. Furthermore, epidermal keratinocytes treated with p38 MAPK inhibitors, both in vivo and in vitro, behave very similarly to Gadd45a-null keratinocytes after UVR. Similarly, Trp53-null mice are unable to attenuate DeltaNp63alpha expression in epidermal keratinocytes after such stress. These findings demonstrate a dependence on Gadd45a-mediated p38 MAPK and p53 activation for proper modulation of DeltaNp63alpha, GSK3beta, and beta-catenin after irradiation. Taken together, our results indicate that Gadd45a is able to repress DeltaNp63alpha, beta-catenin, and consequently MMP expression by two means: by maintaining UVR-induced p38 MAPK and p53 activation and also by associating with the APC complex. This implicates Gadd45a in the negative regulation of cell migration, and invasion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14647429     DOI: 10.1038/sj.onc.1207301

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  22 in total

Review 1.  Gadd45 proteins: relevance to aging, longevity and age-related pathologies.

Authors:  Alexey A Moskalev; Zeljka Smit-McBride; Mikhail V Shaposhnikov; Ekaterina N Plyusnina; Alex Zhavoronkov; Arie Budovsky; Robi Tacutu; Vadim E Fraifeld
Journal:  Ageing Res Rev       Date:  2011-10-05       Impact factor: 10.895

2.  Gadd45a functions as a promoter or suppressor of breast cancer dependent on the oncogenic stress.

Authors:  Jennifer S Tront; Yajue Huang; Albert J Fornace; Albert A Fornace; Barbara Hoffman; Dan A Liebermann
Journal:  Cancer Res       Date:  2010-11-23       Impact factor: 12.701

3.  Gadd45a sensitizes medulloblastoma cells to irradiation and suppresses MMP-9-mediated EMT.

Authors:  Swapna Asuthkar; Arun Kumar Nalla; Christopher S Gondi; Dzung H Dinh; Meena Gujrati; Sanjeeva Mohanam; Jasti S Rao
Journal:  Neuro Oncol       Date:  2011-08-02       Impact factor: 12.300

4.  Iron Regulatory Protein 2 Exerts its Oncogenic Activities by Suppressing TAp63 Expression.

Authors:  Yanhong Zhang; Xiuli Feng; Jin Zhang; Xinbin Chen
Journal:  Mol Cancer Res       Date:  2020-04-10       Impact factor: 5.852

5.  Gadd45a inhibits cell migration and invasion by altering the global RNA expression.

Authors:  Zhanhai Shan; Guiyuan Li; Qimin Zhan; Dan Li
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

6.  FIH-1 engages novel binding partners to positively influence epithelial proliferation via p63.

Authors:  Nihal Kaplan; Ying Dong; Sijia Wang; Wending Yang; Jong Kook Park; Junyi Wang; Elaina Fiolek; Bethany Perez White; Navdeep S Chandel; Han Peng; Robert M Lavker
Journal:  FASEB J       Date:  2019-11-25       Impact factor: 5.191

7.  UVB radiation-induced β-catenin signaling is enhanced by COX-2 expression in keratinocytes.

Authors:  Kimberly A Smith; Xin Tong; Adnan O Abu-Yousif; Carol C Mikulec; Cara J Gottardi; Susan M Fischer; Jill C Pelling
Journal:  Mol Carcinog       Date:  2011-08-18       Impact factor: 4.784

8.  Gadd45a suppresses tumor angiogenesis via inhibition of the mTOR/STAT3 protein pathway.

Authors:  Fang Yang; Weimin Zhang; Dan Li; Qimin Zhan
Journal:  J Biol Chem       Date:  2013-01-17       Impact factor: 5.157

9.  ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage.

Authors:  Yiping Huang; Tanusree Sen; Jatin Nagpal; Sunil Upadhyay; Barry Trink; Edward Ratovitski; David Sidransky
Journal:  Cell Cycle       Date:  2008-09-15       Impact factor: 4.534

Review 10.  Non-classical p38 map kinase functions: cell cycle checkpoints and survival.

Authors:  Tina M Thornton; Mercedes Rincon
Journal:  Int J Biol Sci       Date:  2008-12-19       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.